feedback

Course Director

Claire Harrison, MD
Claire Harrison, MD

Guy's and St Thomas' Hospital
London, England, United Kingdom

Faculty

Alison R. Moliterno
Alison R. Moliterno, MD

Johns Hopkins University School of Medicine
Baltimore, Maryland

John Mascarenhas
John Mascarenhas, MD

Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Srdan Verstovsek
Srdan Verstovsek, MD, PhD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:2.0 Credits
Release Date:2016-Dec-22
Expiration Date:2017-Dec-21
Estimated Time for Completion:120 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

New science has driven innovative medical practice in the recognition and management of polycythemia vera (PV). At a recent live symposium, experts reviewed the latest evidence on how PV is categorized and assessed, its symptom burden, and best practices for clinical management. They also addressed a range of subjects related to these topics, from new thinking on PV diagnostic criteria and aggressive versus indolent disease phenotypes, to the therapeutic implications of higher risk, uncontrolled, or treatment-refractory disease. Personal stories and insights for patient care from these leading experts are also featured in this activity.

Upon completion of this activity, participants should be better able to:
  • Utilize clinical tools and evidence to accurately diagnose or characterize polycythemia vera (PV) and distinguish it from other syndromes with similar presentations
  • Discuss the clinical implications of elevated hematocrit and uncontrolled blood counts in PV
  • Establish the presence of high-risk and treatment-refractory PV in patients with symptoms not responding to current treatment such as phlebotomy or hydroxyurea
  • Select patient-appropriate therapy for individuals in higher risk PV treatment settings, including refractory disease
  • Manage safety considerations in patients with PV on therapy across a range of treatment settings

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, medical oncologists, oncology physician assistants, advanced practice oncology nurses, and other clinicians involved in the care of patients with PV.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 22, 2016 - December 21, 2017
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.

Course Director and Moderator
Claire Harrison, MD
FRCP Consultant Haematologist &
Clinical Director Cancer and Haematology
Guy's and St Thomas' Hospital
London, England, United Kingdom

Claire Harrison, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Novartis AG.
Speakers Bureau participant with Baxalta; CTI BioPharma Corp.; Gilead; Incyte Corporation; Novartis AG; Sanofi; and Shire.
Honoraria from Baxalta; CTI BioPharma Corp.; Gilead; Incyte Corporation; Novartis AG; Sanofi; and Shire.
Advisory Board for Baxalta; CTI BioPharma Corp.; Gilead; Incyte Corporation; Novartis AG; Sanofi; and Shire.

Claire Harrison, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: a number of therapeutic options for polycythemia vera and other myeloproliferative neoplasms.

Faculty
Alison R. Moliterno, MD
Associate Professor of Medicine
Hematology Division, Department of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Alison R. Moliterno, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Incyte Corporation.
Advisory Board for Incyte Corporation.

Alison R. Moliterno, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: a number of therapeutic options for polycythemia vera and other myeloproliferative neoplasms.

John Mascarenhas, MD
Myeloproliferative Disorders Program
Tisch Cancer Institute, Division of Hematology/Oncology
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

John Mascarenhas, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Incyte Corporation and Novartis Corporation for Data Safety Monitoring Board and steering committee member.
Grant/Research Support from CTI BioPharma Corp.; F. Hoffmann-La Roche Ltd.; Incyte Corporation; Janssen Global Services, LLC; Merck & Co., Inc.; Novartis Corporation; and Promedior, Inc. paid to institution.

John Mascarenhas, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: a number of therapeutic options for polycythemia vera and other myeloproliferative neoplasms.

Srdan Verstovsek, MD, PhD
Professor of Medicine
Chief, Section for Myeloproliferative Neoplasms (MPNs)
Department of Leukemia
Director, Clinical Research Center for MPNs
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Bristol-Myers Squibb; Celgene Corporation; CTI BioPharma Corporation; Galena Biopharma, Inc.; Genentech, Inc.; Geron; Gilead; Hoffmann-La Roche Inc.; Incyte Corporation; Lilly Oncology; NS Pharma Inc.; Pfizer; Promedior, Inc.; and Seattle Genetics, Inc.

Srdan Verstovsek, MD, PhD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: a number of therapeutic options for polycythemia vera and other myeloproliferative neoplasms.

CME Reviewer
Vishwanath Sathyanarayanan, MD, DM
Apollo Hospitals
Bangalore, Karnataka, India

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors
Kirk Tacka, PhD
PVI, PeerView Institute for Medical Education

Kirk Tacka, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Incyte Corporation.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2016, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.